Manulife FACT SHEET

MANULIFE DANA EKUITAS TEKNOLOGI KESEHATAN GLOBAL DOLAR

SEP 2025

Investment Objective

To achieve long term capital growth by investing mainly in equity securities of companies which predominant economic activities are in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology sectors, onshore and/or offshore, directly and/or through mutual fund(s).

Risk Classification

Risk classification is based on type of fund.

Low — Mid — High

Money Market — Fixed Income — Balanced — Equity

Fund Information

Inception Date	:	18 Oct 21
Inception Price	:	USD 1.0000
Fund Size	:	USD 542,303.81
Number of unit	:	513,714.69
Net Asset Value/Unit [3]	:	USD 1.0557
Fund Currency	:	USD
Type of fund	:	Equity
Valuation	:	Daily
Custodian Bank	:	Bank DBS Indonesia
Annual Management Fee	:	2.50%
Bloomberg Code	:	MATKGMU IJ
Fund Manager	:	PT Manulife Aset Manajemen Indonesia

Allocation

Equity	:	80 - 100 %
Money Market	:	0 - 20 %

Portfolio

Equity	:	97.25%
Money Market	:	2.75%

Note

1) Annualized (1 year = 365 days) and using compound method (for products that have been more than one year old since inception).
2) The benchmark is MSCI World Healthcare Net Total Return USD Index.
3) The Net Asset Value / Unit has calculated the costs, including fees related to transaction and transaction settlement as well as administration and recording.

Performance Since Inception



Monthly Performance Last 3 Years



Fund Performance

Performance in USD per (30/09/25)	1 mo	3 mo	6 mo	YTD	1 yr	3 yr [1]	5 yr [1]	Since Inception [1]
MANTKG	0.19%	2.23%	-3.56%	1.56%	-9.02%	5.14%	n/a	1.38%
BM [2]	0.97%	3.01%	-1.15%	4.02%	-8.00%	7.21%	n/a	2.71%

Yearly Performance	2024	2023	2022	2021	2020	2019	2018	2017
MANTKG	2.19%	1.17%	-4.60%	n/a	n/a	n/a	n/a	n/a
BM [2]	0.94%	3.76%	-5.68%	n/a	n/a	n/a	n/a	n/a

Top Holdings* & Sector Allocation

Mutual Fund - BlackRock Global Funds - World Healthscience Fund



Non Affiliates

Investment Manager Commentary

Global equities continued its positive trend, posting positive return in September. US central bank cut benchmark rate by 25bps inline with market expectation, its first cut since December 2024. However Fed Chair Jerome Powell struck a cautious tone, acknowledged the economy faces a “challenging situation”, caught between inflation risks and labour market concerns. Economic data largely validated this measured approach as core inflation held steady at 2.9% YoY, stubbornly above target. The healthcare sector underperformed in September due to the US government imposing 100% tariffs on imported patented pharmaceutical products, unless the company is building manufacturing plant in the US. However market sentiment improved following Pfizer that reached a deal with US government to lower prescription medicine prices and commitment to invest USD70 billion in the US. The deal drove optimism that other pharma companies could reach similiar deal.

Manulife Indonesia

Established in 1985, PT Asuransi Jiwa Manulife Indonesia (Manulife Indonesia) is part of Manulife Financial Corporation Group, a Canadian financial services group that operates in Asia, Canada and the United States. Manulife Indonesia offers a wide range of financial services, including life insurance, accident and health insurance, investment and pension plans to individual customers and group clients in Indonesia. Through a network of almost 11,000 employees and professional agents spread across more than 30 sales offices, Manulife Indonesia serves around 2 million customers in Indonesia.

PT Asuransi Jiwa Manulife Indonesia are licensed and supervised by the Otoritas Jasa Keuangan (OJK). To learn more about Manulife Indonesia, follow us on Facebook, Twitter, Instagram, YouTube, or visit www.manulife.co.id.